Journal Article

DZNE-2020-05119

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data.

Gomm, W. (First author)DZNE* ; von Holt, K.DZNE* ; Thomé, F.DZNE* ; Broich, K. ; Maier, W.DZNE* ; Weckbecker, K. ; Fink, A.DZNE* ; Doblhammer-Reiter, G.DZNE* ; Haenisch, B. (Last author)DZNE*

2016
IOS Press Amsterdam

This record in other databases:    

Please use a persistent id in citations: doi:10.3233/JAD-151006

Abstract: While acute detrimental effects of benzodiazepine (BDZ), and BDZ and related z-substance (BDZR) use on cognition and memory are known, the association of BDZR use and risk of dementia in the elderly is controversially discussed. Previous studies on cohort or claims data mostly show an increased risk for dementia with the use of BDZs or BDZRs. For Germany, analyses on large population-based data sets are missing.To evaluate the association between regular BDZR use and incident any dementia in a large German claims data set.Using longitudinal German public health insurance data from 2004 to 2011 we analyzed the association between regular BDZR use (versus no BDZR use) and incident dementia in a case-control design. We examined patient samples aged≥60 years that were free of dementia at baseline. To address potential protopathic bias we introduced a lag time between BDZR prescription and dementia diagnosis. Odds ratios were calculated applying conditional logistic regression, adjusted for potential confounding factors such as comorbidities and polypharmacy.The regular use of BDZRs was associated with a significant increased risk of incident dementia for patients aged≥60 years (adjusted odds ratio [OR] 1.21, 95% confidence interval [CI] 1.13-1.29). The association was slightly stronger for long-acting substances than for short-acting ones. A trend for increased risk for dementia with higher exposure was observed.The restricted use of BDZRs may contribute to dementia prevention in the elderly.

Keyword(s): Aged (MeSH) ; Aged, 80 and over (MeSH) ; Benzodiazepines: adverse effects (MeSH) ; Benzodiazepines: chemistry (MeSH) ; Case-Control Studies (MeSH) ; Dementia: chemically induced (MeSH) ; Dementia: diagnosis (MeSH) ; Dementia: epidemiology (MeSH) ; Drug Utilization: statistics & numerical data (MeSH) ; Drug Utilization: trends (MeSH) ; Female (MeSH) ; Follow-Up Studies (MeSH) ; Germany: epidemiology (MeSH) ; Humans (MeSH) ; Insurance Claim Reporting: statistics & numerical data (MeSH) ; Insurance Claim Reporting: trends (MeSH) ; Longitudinal Studies (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Risk Factors (MeSH) ; Benzodiazepines

---

Contributing Institute(s):

1. Pharmacoepidemiology (AG Hänisch)
2. U Clinical Researchers - Bonn (U Clinical Researchers - Bonn)
3. Demographic Studies (AG Doblhammer)

Research Program(s):

1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)
2. 345 - Population Studies and Genetics (POF3-345) (POF3-345)

Appears in the scientific report 2016

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---